Subtype
Pancreatic Adenocarcinoma
CI-CAN-00006283Explore in graph →
357 active trials5 approved drugs26 evidence items
- NCIt
- C8294
- OncoTree
- PAAD
- DOID
- 4074
- UMLS CUI
- C0281361
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006283Explore in graph →
Clinical trials
916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (136)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01447732 | Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 71 | Kyowa Kirin Co., Ltd.INDUSTRY | 0 | Apr 29, 2024 | clinicaltrials |
| NCT03307564 | Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer | completed | N/A | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04143152 |
| Pancreatic Cancer Biomarker Study |
| unknown |
| — |
| 300 |
| Van Andel Research InstituteOTHER |
| 1 |
| Apr 23, 2024 |
| clinicaltrials |
| NCT06349278 | Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX(PDAC-LIV) | recruiting | N/A | 15 | Laval UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06361030 | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05984810 | NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101(FLUOPANC-II) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05476978 | Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions | completed | — | 130 | Huazhong University of Science and TechnologyOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06341725 | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging | terminated | — | 2 | Paolo Giorgio Arcidiacono, MDOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03373188 | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | completed | Phase 1 | 10 | Emory UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT04793633 | Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer | enrolling by invitation | — | 500 | Adenocyte, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06302881 | Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma | unknown | — | 207 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT04119362 | PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer(PARAGON) | completed | — | 469 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06272162 | Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy(LAPSTAR) | not yet recruiting | N/A | 150 | UMC UtrechtOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT05161013 | A Proof-of-Concept Study Evaluating LINFU™ | completed | N/A | 12 | Adenocyte, LLCINDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04305067 | PRECISE: Pancreatic Cancer and Exercise | completed | N/A | 8 | Queen's University, BelfastOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT01959139 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 126 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04406571 | Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer(CAPANCOVID-19) | completed | — | 700 | CHU de ReimsOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06214533 | Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery(CEBOIDS) | unknown | N/A | 60 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT04883450 | PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer(PRO-TECT) | unknown | — | 126 | Kaiser PermanenteOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | terminated | Phase 1 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT01825603 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | completed | Phase 1 | 17 | University of NebraskaOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis(ROSALIND) | recruiting | — | 1,020 | Cure 51OTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 23 | Albert Einstein College of MedicineOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06147154 | Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer Patients | completed | — | 23 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06151691 | Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach | unknown | — | 51 | Fudan UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05964621 | Venous Thromboembolism in Primary Pancreatic Tumour Resection(PaTR-VTE) | unknown | — | 64 | University of ThessalyOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02231723 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | completed | Phase 1 | 139 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(RELIANT) | terminated | Phase 3 | 43 | Corcept TherapeuticsINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04596865 | Recurrence After Whipple's (RAW) Study | completed | — | 1,484 | University Hospital Plymouth NHS TrustOTHER | 8 | Nov 18, 2023 | clinicaltrials |
| NCT06135649 | Dissecting the Pattern of Nodal Spread in Post-neoadjuvant Pancreatoduodenectomy | unknown | — | 850 | Universita di VeronaOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 7 | Zhen Wang, MDOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04575363 | RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer(PaCaBioMarkeR) | recruiting | N/A | 90 | CHU de ReimsOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02178436 | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | Mohammed Najeeb Al HallakOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT00020345 | Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 34 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT05752812 | The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer | recruiting | — | 1,500 | Medical University of ViennaOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02767700 | NGS and TME for Evidence-based Treatment of Pancreatic Cancer(PePaCaKa-01) | completed | — | 39 | Karolinska University HospitalOTHER | 0 | Oct 24, 2023 | clinicaltrials |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 29, 2024source: clinicaltrials